Cladribine therapy for systemic mastocytosis

Blood

Volumn 102, Issue 13, 2003, Pages 4270-4276

  Kluin Nelemans, Hanneke C ^a   Oldhoff, J Marja ^b   Van Doormaal, Jasper J ^b   Van't Wout, Jan W ^b   Verhoef, Gregor ^b   Gerrits, Wim B J ^b   Van Dobbenburgh, O Aart ^b   Pasmans, Suzanne G ^b   Fijnheer, Rob ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMIODARONE; CLADRIBINE; CLEMASTINE; CORTICOSTEROID; COTRIMOXAZOLE; FLUCONAZOLE; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYUREA; N METHYLHISTAMINE; N METHYLIMIDAZOLEACETIC ACID; PREDNISOLONE; PREDNISONE; TRYPTASE; UNCLASSIFIED DRUG; VALACICLOVIR;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG INFUSION; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEMATOLOGIC MALIGNANCY; HERPES ZOSTER; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MAST CELL; MEDIATOR RELEASE; METABOLITE; NEUTROPENIA; NONHUMAN; PANCYTOPENIA; PILOT STUDY; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RELAPSE; REMISSION; SIDE EFFECT; SYSTEMIC MASTOCYTOSIS; THROMBOCYTOPENIA; TOXICODERMA; TREATMENT OUTCOME; URINARY EXCRETION; URTICARIA PIGMENTOSA; VEIN THROMBOSIS;

EID: 0345167915     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-05-1699     Document Type: Article

References (25)

1. Travis WD, Li C-Y, Bergstralh MS, Yam LT, Swee RG. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine. 1988;67:345-368.
2. Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol. 1991;96:2S-4S.
3. Valent P, Horny H-P, Li C-Y, et al. Mastocytosis (mast cell disease). In: Jaffe ES, Harris NL, Stein H, Vardiman J, eds. WHO Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:292-302.
4. Worobec AS. Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am. 2000;14:659-687.
5. Ronnov-Jessen D, Lovgreen Nielsen P, Horn T. Persistence of systemic mastocytosis after allogeneic bone marrow transplantation in spite of complete remission of the associated myelodysplastic syndrome. Bone Marrow Transplant. 1991;8:413-415.
6. Kluin-Nelemans HC, Jansen JH, Breukelman H, et al. Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med. 1992;326:619-623.
7. Pulik M, Lionnet F, Petit A, Genet P, Gaulier A. Long-term response to interferon-alpha in a patient with systemic mastocytosis and chronic myelomonocytic leukemia. Am J Hematol. 1994;47:66.
8. Czarnetzki BM, Algermissen B, Jeep S, et al. Interferon treatment of patients with chronic urticaria and mastocytosis. J Am Acad Dermatol. 1994;30:500-501.
9. Delaporte E, Piérard E, Wolthers BG, et al. Interferon-alpha in combination with corticosteroids improves systemic mast cell disease. Br J Dermatol. 1995;132:479-482.
10. Lippert U, Henz BM. Long-term effect of interferon alpha treatment in mastocytosis. Br J Dermatol. 1996;134:1164-1165.
11. Butterfield JH. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol. 1998;138:489-495.
12. Lehmann T, Lämmle B. IFN-alpha treatment in systemic mastocytosis. Ann Hematol. 1999;78:483-484.
13. Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol. 2002;81:677-690.
14. Tefferi A, Li C-Y, Butterfield JH, Hoagland HC. Treatment of systemic mast-cell disease with cladribine. N Engl J Med. 2001;344:307-309.
15. Granerus G, Lönnqvist B, Nystrand J, Roupe G. Serum tryptase measured with B12 and G5 antibody-based immunoassays in mastocytosis patients and its relation to histamine turnover. Br J Dermatol. 1998;139:858-861.
16. Keijzer JJ, Breukelman H, Wolthers BG, Heuvel van den M, Kromme N, Berg W. Urinary excretion of histamine and some of its metabolites in man: influence of the diet. Agents Actions. 1984;15:189-194.
17. Keijzer JJ, Monchy de JGR, Doormaal van JJ, Voorst Vader van PC. Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites. N Engl J Med. 1983;309:1603-1605.
18. Keijzer JJ, Wolthers BG, Muskiet FAJ, Kauffman HF, Groen A. Determination of N-methylhistamine in plasma and serum by isotope dilution mass fragmentography. Clin Chim Acta. 1981;113:165-173.
19. Oosting E, Keyzer JJ, Wolthers BG, Scholtis RJH. Age dependent normal values of histamine and histamine metabolites in human urine. Agents Actions 1988;23:307-310.
20. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 1995;92:10560-10564.
21. Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet. 1996;12:312-314.
22. Valent P, Akin C, Sperr WR, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res. 2003;27:635-641.
23. Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol. 2002;119:1090-1097.
24. Saven A, Burian C. Cladribine activity in adult Langerhans-cell histiocytosis. Blood. 1999;93:4125-4130.
25. Kirshenbaum A. Regulation of mast cell number and function. Hematol Oncol Clin North Am. 2000;14:497-516.